A visual MSLN target evaluation report for ovarian cancer, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.

A visual B7-H3 target evaluation report for NSCLC, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.

Bring target, disease, drug, clinical, regulatory, chemistry, biologics, and market intelligence directly into your agent workflows.

Explore the booming mRNA therapeutics market, projected to exceed USD 100 billion by 2028. Learn how mRNA drugs work, their key advantages, and the global leaders driving innovation in vaccines and cancer treatment.

Nav1.8 inhibitors represent a breakthrough in pain therapeutics, offering a non-addictive alternative to opioids.

This article reviews the biological mechanisms of FGFR dysregulation and clinical advances of FGFR inhibitors like erdafitinib in treating urothelial carcinoma and other malignancies with FGFR alterations.

Explore major breakthroughs in antibody-drug conjugates (ADCs) in 2024, including key targets like Trop-2, HER2, EGFR, and c-Met. Learn about landmark drug approvals, late-stage clinical trials, and the future of precision cancer therapy.

B7-H3 (CD276), a type I transmembrane glycoprotein, has garnered significant attention due to its overexpression in a wide range of human cancers.

A landmark ruling by Japan’s IP High Court awarded record-breaking $150 million damages in the Nalfurafine (Remitch®) patent dispute. This case reshapes how pharmaceutical companies approach patent term extensions, generic entry strategies, and IP litigation risks.

On June 4, 2025, the CAFC issued a precedential decision in a patent infringement case involving mRNA-based COVID-19 vaccines, addressing whether the patentee’s “custom” definition of a term constituted infringement.

Radiopharmaceuticals, which combine radioactive isotopes with specific molecular carriers, are ushering in a new era of personalized medicine.

In 2024, the field of cancer therapeutics has witnessed remarkable progress in targeting Claudin 18.2 (CLDN18.2).